News stories about EXACT Sciences (NASDAQ:EXAS) have trended somewhat positive on Sunday, Accern Sentiment Analysis reports. The research firm identifies positive and negative media coverage by monitoring more than twenty million news and blog sources in real time. Accern ranks coverage of publicly-traded companies on a scale of -1 to 1, with scores closest to one being the most favorable. EXACT Sciences earned a media sentiment score of 0.21 on Accern’s scale. Accern also assigned headlines about the medical research company an impact score of 45.8264260147832 out of 100, meaning that recent media coverage is somewhat unlikely to have an effect on the company’s share price in the immediate future.
These are some of the headlines that may have impacted Accern Sentiment Analysis’s scoring:
Several brokerages have recently issued reports on EXAS. Leerink Swann restated an “outperform” rating and issued a $50.00 price objective (up previously from $45.00) on shares of EXACT Sciences in a research note on Thursday, September 21st. BidaskClub raised EXACT Sciences from a “hold” rating to a “buy” rating in a report on Thursday, December 21st. William Blair reissued a “buy” rating on shares of EXACT Sciences in a report on Wednesday. Canaccord Genuity reaffirmed a “buy” rating and issued a $60.00 price target (up from $45.00) on shares of EXACT Sciences in a report on Tuesday, October 3rd. Finally, Zacks Investment Research raised EXACT Sciences from a “hold” rating to a “buy” rating and set a $51.00 price target for the company in a report on Tuesday, September 26th. Eight analysts have rated the stock with a hold rating and ten have given a buy rating to the stock. The company currently has a consensus rating of “Buy” and a consensus price target of $50.58.
EXACT Sciences (NASDAQ:EXAS) opened at $52.62 on Friday. The company has a debt-to-equity ratio of 0.01, a quick ratio of 9.98 and a current ratio of 10.34. EXACT Sciences has a 12-month low of $16.95 and a 12-month high of $63.60.
EXACT Sciences (NASDAQ:EXAS) last released its earnings results on Monday, October 30th. The medical research company reported ($0.23) EPS for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.30) by $0.07. EXACT Sciences had a negative return on equity of 30.32% and a negative net margin of 60.71%. The firm had revenue of $72.60 million for the quarter, compared to analysts’ expectations of $65.03 million. During the same quarter in the previous year, the business posted ($0.36) EPS. The business’s quarterly revenue was up 158.4% compared to the same quarter last year. research analysts predict that EXACT Sciences will post -1.09 EPS for the current fiscal year.
In related news, CEO Kevin T. Conroy sold 137,805 shares of the stock in a transaction on Thursday, November 9th. The stock was sold at an average price of $59.14, for a total value of $8,149,787.70. Following the sale, the chief executive officer now owns 967,867 shares in the company, valued at approximately $57,239,654.38. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, SVP D Scott Coward sold 1,665 shares of the stock in a transaction on Wednesday, January 3rd. The shares were sold at an average price of $52.54, for a total value of $87,479.10. Following the completion of the sale, the senior vice president now owns 37,558 shares in the company, valued at approximately $1,973,297.32. The disclosure for this sale can be found here. In the last quarter, insiders have sold 610,433 shares of company stock worth $34,341,306. Company insiders own 4.00% of the company’s stock.
COPYRIGHT VIOLATION WARNING: “EXACT Sciences (NASDAQ:EXAS) Given Daily Media Impact Rating of 0.21” was posted by Dispatch Tribunal and is the property of of Dispatch Tribunal. If you are accessing this piece on another site, it was illegally stolen and republished in violation of U.S. & international copyright and trademark law. The correct version of this piece can be viewed at https://www.dispatchtribunal.com/2018/01/14/exact-sciences-exas-earning-somewhat-favorable-news-coverage-analysis-shows.html.
About EXACT Sciences
Exact Sciences Corporation is a molecular diagnostics company. The Company focuses on the early detection and prevention of some forms of cancer. It offers a non-invasive screening test called Cologuard for the early detection of colorectal cancer and pre-cancer. Its Cologuard test is a stool-based deoxyribonucleic acid (sDNA) screening test, which utilizes a multi-target approach to detect deoxyribonucleic acid (DNA) and hemoglobin biomarkers associated with colorectal cancer and pre-cancer.
Receive News & Ratings for EXACT Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for EXACT Sciences and related companies with MarketBeat.com's FREE daily email newsletter.